Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Z Li

Showing results (211-220 of 270) with videos related to

Pageof 27
Sort By:
Cell Reports Methods|April 14, 2023
Diagnostic TR-FRET assays for detection of antibodies in patient samplesHong Yue, Radosław P Nowak, Daan Overwijn, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
AIDS (London, England)|June 15, 2021
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteriaJesse Fajnzylber, Radwa Sharaf, John N Hutchinson, et al.
Microbiology Spectrum|May 18, 2026
Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolutionGregory E Edelstein, Tatum N Sass, Rinki Deo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 10, 2021
Fecal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) RNA Is Associated With Decreased Coronavirus Disease 2019 (COVID-19) SurvivalUpasana Das Adhikari, George Eng, Mara Farcasanu, et al.
AIDS Research and Human Retroviruses|May 1, 2023
Current HIV/SIV Reservoir Assays for Preclinical and Clinical Applications: Recommendations from the Experts 2022 NIAID Workshop SummaryBrigitte E Sanders-Beer, Nancie M Archin, Zabrina L Brumme, et al.
Nature Communications|August 22, 2022
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Viral shedding and symptom severity across populations during acute COVID in the ACTIV-2 studyEvelyn Kung, Rinki Deo, Manish C Choudhary, et al.
The New England Journal of Medicine|June 29, 2022
Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) InfectionJulie Boucau, Caitlin Marino, James Regan, et al.
Nature Communications|January 19, 2023
Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.
Pageof 27

Showing results (211-220 of 270) with videos related to

Sort By:
Pageof 27
Cell Reports Methods|April 14, 2023
Diagnostic TR-FRET assays for detection of antibodies in patient samplesHong Yue, Radosław P Nowak, Daan Overwijn, et al.
Biorxiv : the Preprint Server for Biology|September 30, 2024
Modeling suggests SARS-CoV-2 rebound after nirmatrelvir-ritonavir treatment is driven by target cell preservation coupled with incomplete viral clearanceTin Phan, Ruy M Ribeiro, Gregory E Edelstein, et al.
AIDS (London, England)|June 15, 2021
Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteriaJesse Fajnzylber, Radwa Sharaf, John N Hutchinson, et al.
Microbiology Spectrum|May 18, 2026
Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolutionGregory E Edelstein, Tatum N Sass, Rinki Deo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 10, 2021
Fecal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Cov-2) RNA Is Associated With Decreased Coronavirus Disease 2019 (COVID-19) SurvivalUpasana Das Adhikari, George Eng, Mara Farcasanu, et al.
AIDS Research and Human Retroviruses|May 1, 2023
Current HIV/SIV Reservoir Assays for Preclinical and Clinical Applications: Recommendations from the Experts 2022 NIAID Workshop SummaryBrigitte E Sanders-Beer, Nancie M Archin, Zabrina L Brumme, et al.
Nature Communications|August 22, 2022
Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.
Medrxiv : the Preprint Server for Health Sciences|February 12, 2026
Viral shedding and symptom severity across populations during acute COVID in the ACTIV-2 studyEvelyn Kung, Rinki Deo, Manish C Choudhary, et al.
The New England Journal of Medicine|June 29, 2022
Duration of Shedding of Culturable Virus in SARS-CoV-2 Omicron (BA.1) InfectionJulie Boucau, Caitlin Marino, James Regan, et al.
Nature Communications|January 19, 2023
Publisher Correction: Antiviral and clinical activity of bamlanivimab in a randomized trial of non-hospitalized adults with COVID-19Kara W Chew, Carlee Moser, Eric S Daar, et al.
Pageof 27